Gavreto Was Initially Approved By The Nmpa In March 2021 For The Treatment Of Locally Advanced Or Metastatic Ret Fusion-Positive Nsclc After Platinum-Based Chemotherapy. Furthermore, In March 2022, It Received Approval As The First Selective Ret Inhibitor For The Treatment Of Advanced Ret-Altered Thyroid Cancer.The Arrow Study Demonstrated The Efficacy Of Gavreto
